MA29273B1 - Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur - Google Patents

Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur

Info

Publication number
MA29273B1
MA29273B1 MA30171A MA30171A MA29273B1 MA 29273 B1 MA29273 B1 MA 29273B1 MA 30171 A MA30171 A MA 30171A MA 30171 A MA30171 A MA 30171A MA 29273 B1 MA29273 B1 MA 29273B1
Authority
MA
Morocco
Prior art keywords
immunosuppresseur
xolair
omalizumab
agent
synergistic combination
Prior art date
Application number
MA30171A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29273B1 publication Critical patent/MA29273B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTICORPS ANTI-IGE, ET AU MOINS UN AGENT IMMUNOSUPPRESSEUR ADDITIONNEL, DANS LAQUELLE LES INGRÉDIENTS ACTIFS SONT PRÉSENTÉS DANS CHAQUE CAS SOUS FORME LIBRE OU SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, ET ÉVENTUELLEMENT AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE, ET SONT DESTINÉS À ÊTRE ADMINISTRÉ SIMULTANÉMENT, SÉPARÉMENT, OU SUCCESSIVEMENT.
MA30171A 2005-02-04 2007-08-28 Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur MA29273B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502358.5A GB0502358D0 (en) 2005-02-04 2005-02-04 Organic compounds

Publications (1)

Publication Number Publication Date
MA29273B1 true MA29273B1 (fr) 2008-02-01

Family

ID=34355808

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30171A MA29273B1 (fr) 2005-02-04 2007-08-28 Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur

Country Status (20)

Country Link
US (1) US20080206237A1 (fr)
EP (1) EP1846031A1 (fr)
JP (1) JP2008528650A (fr)
KR (1) KR20070100344A (fr)
CN (1) CN101111265A (fr)
AR (1) AR053541A1 (fr)
AU (1) AU2006210098A1 (fr)
BR (1) BRPI0607349A2 (fr)
CA (1) CA2595976A1 (fr)
GB (1) GB0502358D0 (fr)
GT (1) GT200600023A (fr)
IL (1) IL184713A0 (fr)
MA (1) MA29273B1 (fr)
MX (1) MX2007009436A (fr)
NO (1) NO20074497L (fr)
PE (1) PE20061203A1 (fr)
RU (1) RU2007132980A (fr)
TN (1) TNSN07304A1 (fr)
TW (1) TW200640487A (fr)
WO (1) WO2006082052A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006212866A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
PT3190128T (pt) * 2008-09-17 2019-02-07 Xencor Inc Composições e métodos para tratar distúrbios mediados pela ige
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ ＧＰＶＩに対する新規アンタゴニスト抗体および該抗体のＦａｂフラグメントならびにこれらの使用
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
US10947320B2 (en) 2015-12-18 2021-03-16 University Of Notre Dame Du Lac Covalent heterobivalent antibody inhibitors and ligands
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (fr) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-sclérostine et procédés d'utilisation
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
WO2025010086A1 (fr) 2023-07-05 2025-01-09 Genentech, Inc. Thérapie à base d'anticorps anti-ige pour allergies alimentaires multiples

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20070100344A (ko) 2007-10-10
EP1846031A1 (fr) 2007-10-24
MX2007009436A (es) 2007-08-17
US20080206237A1 (en) 2008-08-28
TW200640487A (en) 2006-12-01
IL184713A0 (en) 2007-12-03
GT200600023A (es) 2006-08-16
TNSN07304A1 (en) 2008-12-31
AR053541A1 (es) 2007-05-09
BRPI0607349A2 (pt) 2009-09-01
CN101111265A (zh) 2008-01-23
GB0502358D0 (en) 2005-03-16
JP2008528650A (ja) 2008-07-31
WO2006082052A1 (fr) 2006-08-10
RU2007132980A (ru) 2009-03-10
PE20061203A1 (es) 2006-12-19
AU2006210098A1 (en) 2006-08-10
NO20074497L (no) 2007-10-26
CA2595976A1 (fr) 2006-08-10

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
EP1354590A4 (fr) Medicaments contre les defaillances articulaires
CY1114594T1 (el) Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη
NO2014016I2 (no) Dimetylfumarat
IL165601A0 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
WO2002028999A3 (fr) Profils d'expression genique dans les cellules granulocytaires
BRPI0414721A (pt) formulações estabilizadas de fosfatidilserina
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2002011694A3 (fr) Compositions et formes posologiques en vue d'une application dans la cavite orale dans le cadre du traitement de mycoses
SE9902935D0 (sv) Pharmaceutical compositions
WO2003106640A3 (fr) Procedes et compositions de ciblage cellulaire